Skip to main content

Table 6 Drugs used for trigeminal neuralgia at initial and follow-up assessments

From: Favourable prognosis of trigeminal neuralgia when enrolled in a multidisciplinary management program - a two-year prospective real-life study

  Initial assessment (n = 103) * Dose Range (initial) 3 months assessment (n = 60) 6 months assessment (n = 71) 12 months assessment (n = 60) Two-year assessment (n = 103) Dose range (two-year) P-value#
N (%) Cl mg N (%) Cl N (%) Cl N (%) Cl N (%) Cl mg  
Carbamazepine 29 (28) 19–37 100–1600 22 (36) 24–47 22 (31) 21–43 15 (25) 14–37 20 (19) 12–28 200–1400 0.13
Oxcarbazepine 20 (19) 12–28 300–2400 20 (33) 22–46 18 (25) 16–37 18 (30) 19–43 30 (29) 21–39 300–2700 0.076
Gabapentin 29 (28) 20–37 600–4500 14 (23) 12–33% 17 (24) 14–36 12 (20) 10–32 24 (23) 15–32 600–3600 0.33
Pregabalin 8 (8) 3–13 150–600 7 (12) 3–19 2 (3) 0–9 6 (10) 4–21% 7 (7) 3–14 150–600 1.00
Baclofen 4 (4) 0–10 15–70 1 (1) 0–5 40 N/A
Valproate 4 (4) 0–10 500–1200 1 (2) 0–5 1 (1) 0–4 1 (2) 0–5 N/A
Tricyclic antidepressants 3 (3) 0–8 100–200 1 (2) 0–5 2 (2) 0–6 2 (3) 1–9 4 (4) 0–10 40–100 1.00
Lamotrigine 3 (3) 0–8 250–800 4 (6) 3–13 4 (6) 0–14 3 (5) 0–14 7 (7) 2–14 125–700 0.22
Phenytoin 1 (1) 0–5 50 N/A
Morphine-like drugs 2 (2) 0–7 200 2 (2) 0–7 200 N/A
Paracetamol 4 (4) 0–10 1000–4000 1 (2) 0–5 1 (2) 0–5 3 (3) 0–8 1000–4000 1.00
NSAID 2 (2) 0–7 400–1200 2 (3) 1–9 1 (2) 0–5 1 (1) 0–5 Md N/A
Verapamil 1 (1) 0–7 480 1 (2) 0–5 N/A
Eslicarbazepine 1 (1) 0–7 800 N/A
Levetiracetam 1 (1) 0–7 1500 N/A
  1. aFishers exact test. *Represents the drugs that patients reported at their initial visit at DHC, i.e. the drugs they were using at the time of referral. #Mc Nemars test based on data from initial vs. two-year assessment. CL = 95% confidence limits. N/A = not applicable, Md = missing data